Simultaneous measurement of multiple cytokines

By Dr Matt Wilkinson

- Last updated on GMT

Researchers at Randox, UK, have developed a biochip that enables
the simultaneous measurement of 12 human cytokines from human serum
samples enabling cytokine studies to be conducted faster.

Cytokines are small regulatory proteins produced by various cell types and function as intracellular chemical messengers and control many immune and inflammatory responses.

They are normally released in picomolar amounts, making their detection somewhat difficult and are involved in a variety of immunological, inflammatory and infectious diseases.

The new research, published in the Journal of Proteome Research , describes how a biochip array can be used to simultaneously measure 12 different cytokines from up to 54 different biological samples.

As such this new tool may enable researchers conducting clinical studies on diseases such as cancer, cardiovascular conditions, autoimmunity, nervous system dysfunction, ageing and sepsis to study the effects of drugs on these potential biomarkers of disease progression.

Indeed, the Northwick Park tragedy that occurred while researchers were conducting 'first-in-man' clinical trials on TeGenero's TGN1412, which instead of subtly 're-tuning' the immune system as the developer hoped sent the immune system into overdrive and caused a 'cytokine storm' that attacked healthy organs with tragic results.

While the new system would have not been able to help minimise the tragedy, it may have enabled researchers to gather data quicker and followed the progression of the problem more closely than the currently used ELISA (enzyme linked immunosorbent assay) tests.

The biochip uses a sandwich immunoassay in which monoclonal capture antibodies are bound and stabilised to predefined positions on a pre-activated biochip surface.

These antibodies specifically bind to either one of 7 interleukins (IL-1a, IL-1ß, IL-2, IL-4, IL-6, IL-8 or IL-10) vascular endothelial growth factor (VGEF), interferon gamma (IFN?), epidermal growth factor (EGF), monocyte chemotactic protein 1 (MCP-1) or tumour necrosis factor alpha (TNFa).

After the addition of a small amount of a human serum sample was added to the biochip, a series of incubation steps were required before the results could be read using Randox Laboratories' Evidence Investigator system.

The new assay acheived sensitivity ranging from 0.12pg per ml for the IL-6 analyte, to 2.12 pg per ml for IL-4.

"This approach reduces the sample / reagent volume consumed with the corresponding effects in the cost effectiveness and can provide new insights in the clinical relevance of cytokines as it enables simultaneous measurement of very low levels of these compounds in clinical samples," write the authors.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars